Table 1 Results of Modified Payback Method of Assessment and Non-Monetisable Consequences. HCRA Impact metrics by Payback domains
Domains | Sub-categories | Metric | Result |
|---|---|---|---|
Advance knowledge | Publications, books and published presentations | No. of cancer-related articles published by HCRA members in peer-reviewed journals including original research, protocols and editorials (total) | 3822 |
No. of citations (published papers) | 75,736 | ||
Average no. of citations per paper | 20 | ||
No. of book chapters authored | 84 | ||
No. of books authored | 6 | ||
No. of citations of book chapters | 58 | ||
Newsletters/ Reports | Weekly rapid-fire newsletters to HCRA membership | 320 | |
No. of subscribers | 567 | ||
Quarterly Connect newsletters | 32 | ||
No. of subscribers | 697 | ||
No. of reports | 2 | ||
Social media | Tweets over HCRA lifetime (since June 2013) | 1585 | |
Twitter followers | 720 | ||
Approximate Tweet impressions per month | 3400–25,000 | ||
No. of Facebook followers | 405 | ||
No. of Facebook posts | 58 | ||
No. reached per Facebook post | 50–4400 | ||
Capacity and capability | PhDs | No. of PhD candidates receiving Top Up funds | 23 |
No. of PhD candidates supported via leveraged UoN scholarships | 13 | ||
Fellowships | No. of HCRA clinical fellowships offered | 10 | |
No. of leveraged career development fellowships administered | 4 | ||
No. of leveraged career advancement fellowships administered | 5 | ||
Travel grants | No. of HCRA sponsored travel grants | 118 | |
No. awarded international travel for educational exchange | 4 | ||
No. of leveraged travel grants administered by HCRA | 11 | ||
Funded projects | No. of HCRA funded projects and systematic reviews | 85 | |
Infrastructure support | No. of HCRA projects/researchers awarded infrastructure support | 35 | |
No. of leveraged software licenses and subscriptions funded | 5 | ||
Publication support | No. of publications financially supported by HCRA (e.g. systematic review salary support) | 9 | |
No. of publications receiving leveraged financial support administered by HCRA (e.g. publication costs) | 16 | ||
Statistical support | No. of projects receiving HCRA funded statistical support | 40 | |
Consumer Advisory Panel | No. of projects received advice from consumer panel | 33 | |
Matchmaking service | No. of clinicians and researchers matched | 39 | |
Knowledge translation consultations | No. of researchers who received support for a knowledge translation consultation | 3 | |
Future Leaders Group (FLG) Awards | No. of recipients of leveraged FLG Awards | 12 | |
Media support | No. of leveraged Media Makeover packages awarded (FLG Funds) | 4 | |
Education and Training Events | No. of HCRA sponsored events | 6 | |
Total no. of capacity building events | 85 | ||
No. of seminars | 32 | ||
No. of workshops (including STATA, Behaviours Change Wheel, Twitter, Knowledge Translation, Impact planning and metrics, new NHMRC structure etc.) | 18 | ||
No. of Conferences | 16 | ||
No. of training courses | 7 | ||
Mentor breakfasts (no. of mentors and no. of mentees) | 8 & 17 | ||
No of panels | 5 | ||
No. of ‘Shut up and Write sessions’ for FLG | 6 | ||
No. of other capacity building events | 6 | ||
No. of Consumer & Community Involvement for Researcher training courses | 2 | ||
No of individual attendance | 3198 | ||
Hunter Cancer Research Symposium | No. of symposiums organised | 7 | |
No. of keynote presentations | 16 | ||
No. of invited oral presentations | 76 | ||
No. of competitively chosen rapid-fire oral presentations | 70 | ||
No. of competitively chosen poster presentations | 249 | ||
Clinical trials | No. of clinical trials developed by or with input from HCRA Funded CINSW-defined Category 1 or 2 members | 93 | |
No. of clinical trials partnered with a commercial entity | 11 | ||
No. of participants recruited across 93 trials | 68,784 | ||
Policy | Policy change | No. of policies and guidelines developed by or with input from HCRA Funded CINSW-defined Category 1 or 2 members | 78 |
Cancer coverage | No. of cancers covered (gastrointestinal, lung, brain, head and neck, breast, oesophageal, rectal, bladder, prostate, endometrial, thoracic, colon, lymphoma, pancreatic, Hodgkin lymphoma, skin, liver and spinal) | 18 | |
Biobanking infrastructure | Samples collected | No. of tissue samples collected | 13,017 |
No. of blood samples collected | 38,139 | ||
Total samples collected | 51,156 | ||
Samples distributed | Total samples distributed | 13,691 | |
Tissue cases (sections or cores) | 3453 | ||
IHC slides | 8456 | ||
Bespoke tissue microarrays developed | 70 | ||
Blood aliquots | 2193 | ||
No. of projects with samples distributed | 164 | ||
Staffing | No. of full-time equivalent staff funded by HCRA | 17 | |
Economic benefits | Grants, awards and scholarships leveraged by HCRA members | No. of cancer-related grants, awards and scholarship top ups leveraged by HCRA members | 445 |
Value of leveraged funds (25% attribution) | $38,892,933 | ||
Other resources leveraged by HCRA | Value of Biobank funding leveraged | $ 3,126,860 | |
Value of PhD funding | $ 1,227,843 | ||
Value of fellowships | $ 514,274 | ||
Value of travel grants | $ 13,560 | ||
Value of publication support | $ 52,943 | ||
Value of infrastructure support | $ 7131 | ||
Value of FLG awards | $ 5920 | ||
Value of media packages | $ 1998 | ||
Commercialisation potential | No. of clinical trials that have partnered with a commercial entity | 11 | |
No. of patents developed (No. 35237413) | 1 | ||
No. of license agreements | 1 |